ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in SCLC

I'm Interested!

Please call
1-800-641-2422

An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer

Sex at Birth: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Lung

Study Purpose

An Open-label, Multicenter Study of ZL-1310 as a Single Agent and In Combination with Atezolizumab to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer

Principal Investigator
Afshin Dowlati MD

Department/Division
Cancer (Thoracic)

Locations

UH Seidman Cancer Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: STUDY20231484
StudyID: ZLAB1523
ClinicalTrials.gov: NCT06179069

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422